Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APRICUS: Phase IIb Study of AZD6234 in Adults With Obesity or Overweight With Comorbidities
jRCT2051240175Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing AZD6234 with Placebo (2 arms). Primary endpoints: Percent change in body weight from baseline to week 26 and Proportion of participants with ≥5% weight loss at week 26. Started Nov 2024; status: completed.
02
Drugs
lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051240175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240175.